Sneed Jr. v. AcelRx Pharmaceuticals, Inc.
Opinion
Trial Court Opinion
UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA SAN JOSE DIVISION 6 AARON SNEED JR., Case No. 21-cv-04353-BLF
Plaintiff,
ORDER GRANTING MOTION TO
v. DISMISS WITH LEAVE TO AMEND
ACELRX PHARMACEUTICALS, INC., et [Re: ECF No. 57] al., 11 Defendants. 12 Now before the Court is Defendants’ Motion to Dismiss this putative securities class action. MTD, ECF No. 57. Plaintiffs oppose the Motion. Opp., ECF No. 63. For the reasons discussed at the September 1, 2022 motion hearing and further explained below, the Court GRANTS Defendants’ Motion to Dismiss WITH LEAVE TO AMEND. I. BACKGROUND On June 8, 2021, Plaintiff Aaron Sneed Jr. filed a securities class action suit in this Court alleging violations of various securities laws by AcelRx Pharmaceuticals, Inc. (“AcelRx”), AcelRx Chief Executive Officer Vincent J. Angotti, and AcelRx Chief Financial Officer Raffi Asadorian. Complaint, ECF No. 1. The Court appointed Aaron Sneed Jr. and Yaacov Musry as co-lead …